Category - News

Markets

HCW starts Aeglea BioTherapeutics at buy; PT $20

H.C. Wainwright launched coverage of Aeglea BioTherapeutics (NASDAQ:AGLE) with a “buy” rating and $20 price target. The stock closed at $6.92 on May 21.

May 22, 2019

Developments

Brookline Capital in partnership with Arcadia Securities

Investment banker Brookline Capital Markets entered into a partnership with broker-dealer, Arcadia Securities. The transaction allows Brookline to capitalize on and expand its growing presence in the public capital...

May 22, 2019

Executive Moves

Canopy Growth names Mike Lee as acting CFO

Canopy Growth (TSX:WEED; NYSE:CGC) appointed Mike Lee as acting CFO, effective June 1, and subject to Health Canada security clearance required for all officers and directors of the company.

May 21, 2019

Developments

BeyondSpring presents bone pain relief abstract for Plinabulin at ISPOR

BeyondSpring’s (NASDAQ:BYSI) abstract on its lead asset, Plinabulin, has been accepted for poster presentation at the International Society for Pharmacoeconomics and Outcomes Research 2019 conference May 18-22 in New...

May 21, 2019

Executive Moves

Zenabis provides operational update; appoints Natascha Kiernan to board

Zenabis Global (TSXV:ZENA) provide an update on its recent cannabis production figures, anticipated future harvests, facility construction and licensing status, and medical program update.

May 21, 2019

Developments

Theralase receives patent notice of acceptance for PD compounds in China

The Chinese patent office granted Theralase Technologies (TSXV:TLT; OTCQB:TLTFF) a notice of acceptance for its light activated photodynamic compounds (PDC) intended to safely and effectively destroy various cancers...

May 21, 2019

Developments

FDA accepts Abeona IND for CLN1 disease gene therapy

The FDA has accepted Abeona Therapeutics (NASDAQ:ABEO) IND application for AB-202 for the treatment of CLN1 disease. CLN1 disease, also known as infantile Batten disease, is caused by a mutation in the PPT1 gene. In...

May 21, 2019

Developments

Oragenics enrolls 80 patients in Phase 2 oral mucositis trial

Oragenics (NYSE American:OGEN) has enrolled more than 80 patients in its Phase 2 trial of AG013 for the treatment of oral mucositis (OM). The company also reported that the WHO provided AG013 with the generic name...

May 21, 2019

Developments

Biocept launches liquid biopsy lung cancer test

Biocept (NASDAQ:BIOC) launched its multi-gene liquid biopsy panel for the detection of biomarkers associated with lung cancer. The difficulty of obtaining lung tissue samples from patients has previously limited access...

May 21, 2019

Developments

Compugen doses first patient in advanced solid tumor trial

Compugen (NASDAQ:CGEN) dosed the first patient in its Phase 1 trial of COM701, in combination with Opdivo, in patients with advanced solid tumors. The Phase 1 study will assess the safety and tolerability of COM701, a...

May 21, 2019

Category - News

HCW starts Aeglea BioTherapeutics at buy; PT $20

Brookline Capital in partnership with Arcadia Securities

Canopy Growth names Mike Lee as acting CFO

BeyondSpring presents bone pain relief abstract for Plinabulin at ISPOR

Zenabis provides operational update; appoints Natascha Kiernan to board

Theralase receives patent notice of acceptance for PD compounds in China

FDA accepts Abeona IND for CLN1 disease gene therapy

Oragenics enrolls 80 patients in Phase 2 oral mucositis trial

Biocept launches liquid biopsy lung cancer test

Compugen doses first patient in advanced solid tumor trial

General

More